of the drug. In an experiment on 1,063 patients, the study found that while the drug did not statistically reduce mortality in COVID-19 patients, it did lead to median hospital stays of 11 days, rather than 15 for patients who received a placebo.on Friday with the CEO of Gilead Sciences, the drug's maker. Remdesivir is an anti-viral drug that interferes with the reproduction of viruses in cells, originally intended to treat the MERS and SARS coronaviruses.
"I think this really illustrates what can happen in such a short time," said Deborah Birx of the White House Coronavirus Task Force.of remdesivir in 237 patients published in The Lancet on Wednesday found no clinical benefits to treating COVID-19 patients with the drug, and was halted because it caused a higher percentage of side effects. However, the study did show similar signs of shortening hospital stays, although not to a statistically significant extent.
"The bottom line is that we have shown that an anti-viral can affect this virus and that is in and of itself a great advance," University of Toronto professor Peter Jüni, the editor-in-chief of the journal Trials, told BuzzFeed News. Jüni suggested that larger clinical trials with more patients will show when during an infection patients will benefit the most from infusion with the drug.
CIVIL CASE NO.Dr.Brett Smith, an Assistant Legal Advisor to the FDA and the Arizona State Attorney's Office, is a physician who has authored, lectured, and advised this case.
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NYMag - 🏆 111. / 63 Read more »
Source: CNN - 🏆 4. / 95 Read more »
Source: trtworld - 🏆 101. / 63 Read more »
Source: HuffPostParents - 🏆 414. / 53 Read more »
Source: HuffPostWomen - 🏆 27. / 68 Read more »